15 model-driven-engineering Postdoctoral positions at University of London in United-States
-
for an outstanding, post-doctoral researcher with proven expertise and practical experience in relevant techniques including cell culture, organ-chip models, tissue engineering, and musculoskeletal biology. The PDRA
-
project on Addressing socio-technical limitations of Large Language Models (LLMs), particularly for medical and social computing (https://adsolve.github.io/ ). The role involves developing methods
-
Technology Laboratory (DSTL), Electromagnetic Environment (EME) Hub. About You Applicants should have a PhD in modelling hypothetical scenarios, with and without data, for structured decision-making under
-
including cell culture, organ-chip models, tissue engineering, and musculoskeletal biology. The PDRA will plan and conduct experiments, generate high-quality data, prepare publications, make presentations and
-
will deliver projects that leverage large-scale electronic health record data and rich cytometry data derived from full blood count analysers to develop and refine machine learning models to improved
-
Vitro Models. The project aims to use organ-on-a-chip technology combined with bioengineering approaches to develop, validate and use a suite of vascularised human tendon-chip models. These high quality
-
to work on a project investigating mechanosensing in flies (Diptera). This post will focus on using detailed wing geometry models and free flight kinematic measurements in computational fluid and structural
-
that changes to mechanical sensing, signaling and memory, critically influences the disease onset and progression1. The Iskratsch Group , at the School of Engineering and Materials Science, Queen Mary University
-
materials-based heterostructures , where the 2D nanosheets will act as transducers for electrical sensing applications. This will generate a knowledge-based platform to allow us to rationally engineer 2D
-
of murine models of high-grade lymphoma with the aim of providing pre-clinical evidence to support the development of metabolic inhibitors as novel treatments for lymphoma, alone or in combination with